Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + PD-1 Inhibitor Maintenance in Advanced ESCC
NCT07863141Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Oct 2026; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07863141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863141.